We evaluated the effect of serum on the in vitro activities of 11 antimicrobial agents against gram-negative isolates obtained from 100 patients with nosocomial bacteremia. The test organisms included 25 strains of Pseudomonas aeruginosa and 75 strains of the family Enterobacteriaceae. MICs were determined by broth microdilution with Mueller-Hinton broth alone or supplemented with 25 or 50% pooled, heat-inactivated human serum (25S or 50S, respectively). Among the antibiotics evaluated, the protein binding ranged from 9 to 95%. The antibiotics tested and their MICs for 90% of the strains tested in 50S included ciprofloxacin (0.12 ,Lg/mi), ceftazidime (1 ,ug/ml), imipenem (1 ,ug/ml), aztreonam (4 ,ug/ml), cefpirome (4 ,ug/ml), cefotaxime (16 ,ug/ml), cefoperazone (16 ,Lg/ml), desacetylcefotaxime plus cefotaxime (32 ,ug/ml), ceftriaxone (>32 tig/ml), ticarcillin (128 ,ug/ml), and desacetylcefotaxime (>128 ,ug/ml). MICs for 90% of the strains tested were calculated with 95% confidence intervals to show the precision of the MICs for these strains. With the exceptions of ceftriaxone (>95% protein bound) and cefoperazone (90% protein bound), serum had no significant effect on the in vitro activities of various agents. A fourfold-or-greater increase in the MIC of ceftriaxone was observed in 45 of 100 isolates with 50S and in 30 of 100 isolates with 25S. With cefoperazone, 17 of 100 isolates demonstrated more than 2 twofold dilution increases in 50S. Testing of antibiotics which were less protein bound illustrated minor effects primarily with members of the Enterobacteriaceae. The presence of serum did not adversely affect the in vitro activities of broad-spectrum agents against these nosocomial isolates.
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A reversible, noncovalent binding of antimicrobial agents to human proteins has been described for penicillins (4) and cephalosporins (4) (5) (6) . For the former, increases in MICs were noted in the presence of serum or albumin when tested against both Staphylococcus and Streptococcus species (4) . Similar studies using ceforanide (98% protein bound) showed a protein-binding effect compared with less proteinbound antibiotics (2) . More recently, Jones and Barry demonstrated a protein-binding effect with a broad-spectrum cephalosporin, ceftriaxone, on the MICs for Staphylococcus aureus and selected gram-negative isolates, in which an increase in the MICs resulted in significant susceptibility category changes (5) . With the addition of serum, antibiotic resistance increased in 53% of 34 gram-negative strains tested against ceftriaxone (5) . In contrast, Leggett and Craig demonstrated that the MICs of highly protein-bound antibiotics, such as ceftriaxone (95% protein bound) and cefoperazone (90% protein bound), were enhanced in a linear fashion in the presence of increasing concentrations of serum when tested against Pseudomonas species (6 counts. The microdilution plates were incubated at 35°C in air for 24 h before the MIC for each organism-drug pair was read. The MIC was defined as the lowest antibiotic concentration producing no growth as measured by turbidity on visual inspection. For the purpose of analysis, a variation of 1 twofold dilution was acceptable and considered to be within the limits of error for the procedure. The MIC interpretation for susceptible (S), moderately susceptible (MS), and resistant (R) categories followed recommendations outlined by the National Committee for Clinical Laboratory Standards (8) .
Statistical analysis. The MIC50s and MIC90s for the isolates were calculated from the curve for each antibiotic-organism pair and were used as the variable for statistical analysis. The significant effect of the serum on MICs was estimated by a one-sided Wilcoxon rank sum test. Statistical analyses for the transformation of antibiotic concentrations to their logarithms, with averaging and subsequent estimates of the CT95 limits, were based on the technique reported by Martin et al. (7) . RESULTS Imipenem, ciprofloxacin, cefpirome, and ceftazidime had the broadest in vitro activities against members of the Enterobacteriaceae, with 96 to 100% of all isolates being susceptible in Mueller-Hinton broth without serum (Fig. 1 ).
In addition, ceftazidime had narrow CI95s, showing the precision of the estimated MIC90 and thus further supporting the potency of this antibiotic against the nosocomial isolates tested. The CI95s around the MIC90s show precisely that the MIC90s were not near the breakpoint in these nosocomial gram-negative isolates. Antibiotics are listed by potency against isolates of the Enterobacteriaceae from most to least potent. The percentage of isolates susceptible to each antibiotic is listed above the upper limit of each confidence interval (*). Abbreviations: CIPRO, ciprofloxacin; IPN, imipenem; CPR, cefpirome; CFT, ceftazidime; AZT, aztreonam; CXT, ceftriaxone; CTX, cefotaxime; DES/CTX, desacetylcefotaxime plus cefotaxime (1:1 ratio); CFP, cefoperazone; DES, desacetylcefotaxime; TICAR, ticarcillin.
The nosocomial bloodstream pathogen most likely to display resistance was P. aeruginosa, with 48% of the isolates resistant to one or more of the test antibiotics.
Ceftazidime (MICg, 2.0 ,ug/ml; C195, 1.02 to 3.90) was the most potent of the drugs, with 96% of the isolates being susceptible. Moreover, the upper limit of the CT95 for ceftazidime (3.90 j±g/ml) was far below the breakpoint value, underscoring the potency of ceftazidime. Cefoperazone (MICg, 8.0 ,ug/ml; CT95, 4.10 to 15.61), ciprofloxacin (MIC90, 0.5 ,uglml; C95, 0.26 to 0.98), and imipenem (MIC%0, 2.0 ,ug/ml; CI95, 1.02 to 3.90) were equally potent, with 92% of the isolates being susceptible; however, the upper limit of the C195 in each case was close to the breakpoint MIC.
The addition of serum had no significant adverse effect on the MIC%0s of all drugs against the 75 strains of the Enterobacteriaceae or the 25 P. aeruginosa isolates (Table 1) . No inhibition of organism growth relative to the control (0% serum) was noted in the wells containing either 25 or 50% serum and no antibiotic. With members of the Enterobacteriaceae, the addition of serum affected ceftriaxone most prominently, as noted by the fourfold increase in the MIC50. Although no synergy was noted between desacetylcefotaxime and cefotaxime, the activity of cefotaxime alone and in combination with desacetylcefotaxime was enhanced two-to fourfold against members of the Enterobacteriaceae and P. aeruginosa with the addition of serum (Table 1) . No change with serum was noted for desacetylcefotaxime alone. With strains of the Enterobacteriaceae, 83.6% of the MICs obtained with either 25 or 50% serum were within 1 twofold dilution of the control (0% serum) values (Table 2) .
VOL. 34, 1990 on October 27, 2017 by guest http://aac.asm.org/ Downloaded from Of the beta-lactam antibiotics, ceftriaxone, which is greater than 95% protein bound in 100% serum, was most affected by the addition of 25 or 50% serum (P < 10-5). In 72% (54 of 75) of the isolates, an increase in the MIC of ceftriaxone of . ciprofloxacin, ceftazidime, cefoperazone, and cefpirome. Of these, a significant shift to lower MICs in both 25 and 50% serum with ciprofloxacin was noted (P = 0.002 and P = 0.0002, respectively). In addition, significant decreases in the MICs were noted with cefotaxime (P = 0.004) and cefpirome (P = 0.004) in 50% serum. Decreases in the MICs which were not significant were noted also in 50% serum only for desacetylcefotaxime, aztreonam, imipenem, and ticarcillin.
Very few significant (R-to-S or S-to-R) category changes were observed with P. aeruginosa isolates following the addition of serum (Table 5) . A category change from S to R was observed only with desacetylcefotaxime (1 of 25), and changes from R to S were noted with desacetylcefotaxime plus cefotaxime (1 of 25), cefotaxime (1 of 25), and cefoperazone (1 of 25). Category changes from S to MS and MS to R occurred with ceftriaxone (7 of 25), ciprofloxacin (1 of 25), and cefpirome (1 of 25). Several minor category changes (R to MS and MS to S) were observed with P. aeruginosa following the addition of 50% serum. Changes from R to MS were observed with desacetylcefotaxime plus cefotaxime (3 of 25) and cefotaxime (3 of 25), and changes from MS to S were noted with desacetylcefotaxime plus cefotaxime (8 of 25), cefotaxime (12 of 25), and ceftazidime (1 of 25).
DISCUSSION
This study supports previous findings of the in vitro potency of ciprofloxacin, imipenem, and ceftazidime against nosocomial gram-negative isolates (7, 9) . We also found that cefpirome, ceftriaxone, and aztreonam were reasonably potent in vitro against strains of the Enterobacteriaceae but less active against P. aeruginosa.
The use of the MIC50 and the MIC90 as reflections of the susceptibility of organisms to specific drugs has become a relatively standard method of reporting in vitro antibiotic potency. Recently, Martin et al. (7) responded to a trend of using confidence intervals and introduced the use of confidence intervals above and below the MIC90 to enhance its interpretation for specific drugs and organisms. The confidence interval allows quantification of the precision of the MIC90 estimate. This ultimately would allow clinicians to use susceptibility data to tailor drug choices better and to be confident in the choice made. In our study, confidence intervals were used to evaluate the potency of these antibiotics against pathogens that are nosocomially acquired. Using traditional methods, we evaluated the number of isolates susceptible, the relative MIC90s and the precision of this estimate. The fact that the upper limit of the CT95 is far below the breakpoint for cefotaxime, ceftriaxone, desacetylcefotaxime plus cefotaxime, aztreonam, ciprofloxacin, ceftazidime, cefpirome, and imipenem against the strains of the Enterobacteriaceae tested supports the MIC90 as being a good estimate of the potency of these agents against these organisms. Furthermore, when the upper limit of the C195 is not near the breakpoint, few significant category changes occur in the presence of serum. Likewise, for the P. aeruginosa isolates, the precision of the MIC90 was supported by the narrow CI95. Ceftazidime exhibited a very low upper C195 limit, suggesting a very potent antibiotic against these isolates, none of which were close to the breakpoint. Ciprofloxacin, cefoperazone, and imipenem also were active against these isolates, but the upper limit of the Cl95 was closer to the breakpoint. On the other hand, aztreonam had an MIC90 at the breakpoint, yet the CI95 highlights the need for caution in using this drug against these nosocomial isolates. The relative resistance to the other agents is apparent from the MIC90 estimates and supported by the broad confidence intervals.
The in vitro effect of serum on the antibiotic susceptibility of clinically significant nosocomial gram-negative isolates was seen primarily with an extremely highly protein-bound antibiotic, ceftriaxone. Other antibiotics which were less protein bound experienced only minor effects in 50% serum. Although the protein-binding values of these antibiotics were determined previously in 100% serum (2, 4) , it is not feasible to perform MIC experiments in undiluted (100%) serum. Thus, the actual percentage of each antibiotic which is protein bound in the present study is likely to be less than the values provided in Table 1 . Likewise, the actual effect of serum proteins on antibiotic activity is likely to be less in this in vitro situation (25 to 50% serum) than in the in vivo setting (100% serum). Nevertheless, these values do provide a relative ranking for the tendencies of the various antibiotics to be protein bound.
The effect of serum was seen most prominently in strains of the Enterobacteriaceae, with a statistically significant effect noted for the addition of both 25 and 50% serum with ceftriaxone (95% protein bound) and for 50% serum with cefoperazone (90% protein bound), resulting in an increase in the MICs for the test isolates. No effect of serum was seen among the different species of the Enterobacteriaceae included in this study.
For P. aeruginosa isolates, the only statistically significant effect was a decrease in MICs obtained in both 25 and 50% serum with ciprofloxacin (19 to 28% protein bound) and in 50% serum with cefotaxime (37% protein bound) and cefpirome (9% protein bound).
Our results support, in part, the findings of Jones and Barry, who reported fourfold-or-greater increases in ceftri-axone MICs for 35 to 68% of selected gram-negative isolates when 25 or 50% serum was added to the MIC test broth (5). Although these investigators observed a change to a more resistant susceptibility category for ceftriaxone in 53% of the gram-negative isolates on the addition of serum, we found that the addition of serum produced very few category changes with any of the antibiotics tested in more than 1,100 MIC determinations. One explanation is that the isolates tested by Jones and Barry were selected to include a majority of strains for which the MICs of ceftriaxone were within 2 twofold dilutions of the susceptible breakpoint value. In contrast, our isolates were consecutive nosocomial bloodstream isolates, for the majority of which the MICs of ceftriaxone were significantly lower (strains of the Enterobacteriaceae) or higher (P. aeruginosa) than the breakpoint value (Fig. 1) . Thus, even though serum significantly increased the MICs of ceftriaxone in our study, the increase was not sufficient, in general, to result in a category change. Similar reasoning or the lack of significant (.90%) protein binding can explain the minimal effect of serum on the in vitro susceptibility test results of the other antibiotics included in this study.
The explanation for the enhancing effect of serum on the in vitro activities of several of the test agents against P. aeruginosa is not known but may be related to a putative heat-stable ultrafiltrable serum component, as suggested by Leggett and Craig (6) . These researchers provide evidence for a component in the serum which enhances the activities of broad-spectrum cephalosporins against many gram-negative bacilli. We found this to be true as well with a quinolone, ciprofloxacin, and several beta-lactam antibiotics. Our findings are further supported by those of Jones and Barry, who noted that the in vitro activity of the combination of cefotaxime and desacetylcefotaxime was slightly enhanced in the presence of human serum (5).
In conclusion, our results suggest that the addition of serum, even with the most highly protein-bound antibiotics, results in very few clinically significant changes in the in vitro susceptibility of gram-negative nosocomial bloodstream isolates. On the basis of the data obtained with a representative population of clinically significant nosocomial isolates, we do not support the routine addition of serum to broth used for MIC determinations for nosocomial gramnegative aerobic isolates. In addition, we have provided data to support the use of the CT95 as a measure of the precision of the MIC90 estimate in studies of in vitro antibiotic activity.
